{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Sorrento+Therapeutics%2C+Inc.",
    "query": {
      "sponsor": "Sorrento Therapeutics, Inc.",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Sorrento+Therapeutics%2C+Inc.&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Sorrento+Therapeutics%2C+Inc.&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T10:35:05.142Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03818165",
      "title": "Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Pancreatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "CAR2 Anti-CEA CAR-T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2019-07-29",
      "completion_date": "2021-05-21",
      "has_results": false,
      "last_update_posted_date": "2023-01-17",
      "last_synced_at": "2026-10-10T10:35:05.142Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03818165"
    },
    {
      "nct_id": "NCT04734860",
      "title": "Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "COVI-AMG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-04",
      "completion_date": "2021-11",
      "has_results": false,
      "last_update_posted_date": "2022-02-25",
      "last_synced_at": "2026-10-10T10:35:05.142Z",
      "location_count": 4,
      "location_summary": "Garden Grove, California • Bradenton, Florida • Miami, Florida + 1 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04734860"
    },
    {
      "nct_id": "NCT03229798",
      "title": "Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Migraine Disorders"
      ],
      "interventions": [
        {
          "name": "Sumatriptan Succinate Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Transdermal delivery of sumatriptan succinate",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 19,
      "start_date": "2018-01-17",
      "completion_date": "2018-03-28",
      "has_results": false,
      "last_update_posted_date": "2022-08-10",
      "last_synced_at": "2026-10-10T10:35:05.142Z",
      "location_count": 1,
      "location_summary": "Raleigh, North Carolina",
      "locations": [
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03229798"
    },
    {
      "nct_id": "NCT05361915",
      "title": "Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Abivertinib",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 100,
      "start_date": "2025-09",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-10T10:35:05.142Z",
      "location_count": 2,
      "location_summary": "La Jolla, California • Cleveland, Ohio",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05361915"
    },
    {
      "nct_id": "NCT04905836",
      "title": "Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "COVI-MSC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2021-11-16",
      "completion_date": "2023-03",
      "has_results": false,
      "last_update_posted_date": "2022-04-11",
      "last_synced_at": "2026-10-10T10:35:05.142Z",
      "location_count": 6,
      "location_summary": "Brandon, Florida • Sarasota, Florida • Boise, Idaho + 2 more",
      "locations": [
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04905836"
    },
    {
      "nct_id": "NCT04118868",
      "title": "Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mycosis Fungoides"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab administered using the Sofusa® DoseConnect™",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2022-08-31",
      "completion_date": "2024-03-27",
      "has_results": false,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-10-10T10:35:05.142Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04118868"
    },
    {
      "nct_id": "NCT04728698",
      "title": "Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "ARDS"
      ],
      "interventions": [
        {
          "name": "COVI-MSC",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-03",
      "completion_date": "2021-09",
      "has_results": false,
      "last_update_posted_date": "2021-09-16",
      "last_synced_at": "2026-10-10T10:35:05.142Z",
      "location_count": 1,
      "location_summary": "Fresno, California",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04728698"
    },
    {
      "nct_id": "NCT03682744",
      "title": "CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peritoneal Carcinomatosis",
        "Peritoneal Metastases",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Breast Cancer",
        "Pancreas Cancer",
        "Carcinoembryonic Antigen"
      ],
      "interventions": [
        {
          "name": "anti-CEA CAR-T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-09-13",
      "completion_date": "2021-03",
      "has_results": false,
      "last_update_posted_date": "2022-04-06",
      "last_synced_at": "2026-10-10T10:35:05.142Z",
      "location_count": 2,
      "location_summary": "New Brunswick, New Jersey • Providence, Rhode Island",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03682744"
    },
    {
      "nct_id": "NCT05007418",
      "title": "Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "STI-1492",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2022-10-01",
      "completion_date": "2026-02",
      "has_results": false,
      "last_update_posted_date": "2023-01-17",
      "last_synced_at": "2026-10-10T10:35:05.142Z",
      "location_count": 3,
      "location_summary": "Orange, California • Sacramento, California • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05007418"
    },
    {
      "nct_id": "NCT03226574",
      "title": "Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Intractable Cancer Pain"
      ],
      "interventions": [
        {
          "name": "Resiniferatoxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2017-09-01",
      "completion_date": "2020-06-18",
      "has_results": false,
      "last_update_posted_date": "2020-10-20",
      "last_synced_at": "2026-10-10T10:35:05.142Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Boston, Massachusetts • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03226574"
    }
  ]
}